🏷️ IPO Snapshot
- Price band: ₹ 640–675 per share around
- Issue size: ₹ 1,300 crore in total
- Structure:
- Fresh issue: ₹ 500 crore
- Offer‑for‑sale (OFS) by promoters: ₹ 800 crore
📅 Timeline & Key Dates
- Open: July 29, 2025
- Closes: July 31, 2025
- Allotment date: August 1, 2025
- Refunds & demat credit: August 4, 2025
- Listing date: August 5, 2025 on both BSE and NSE
💰 Minimum Investment
- Lot size: 22 shares
- Min. investment at upper band: ₹ 14,850
- Some sources list ₹ 14,080, but most confirm ₹ 14,850 as accurate for 22 shares at ₹ 675.
📊 Allocation & Investor Reservation
- Retail Individual Investors (RII): ~10%
- Non‑Institutional Investors (NII): ~15%
- Qualified Institutional Buyers (QIB): ~75%
- Anchor Investors got 44–45% of promoter‑offered shares
- The top anchor investors include Government of Singapore, HDFC MF, Goldman Sachs, Abu Dhabi Investment Authority, and others
🔍 Grey Market Premium (GMP)
- Indicative GMP ranges from ₹ 40–217 above the upper band, pointing to potential listing gains of 6%–32%.
- ETMarkets notes GMP at ₹ 45 at open.
- Mint & Moneycontrol report the GMP closer to ₹ 200–217, signaling about 30% expected listing gain.
🏢 Business & Financial Highlights
- Core business: CP Plus brand — distributor and solutions provider in electronic security and surveillance (CCTV, networking, access control)
- Network: Present in over 650 cities through ~15,000 channel partners; strong pan‑India presence
Financial growth:
Revenue: ₹ 2,782 Cr (FY23) → ₹ 3,112 Cr (FY25)- Net profit jumped from ₹ 115 Cr (FY24) to ₹ 3,513 Cr (FY25) — analysts flag margin expansion and possible anomalies
🚩 Risks & Analyst Commentary
- Challenges:
- Heavy working capital requirements
- Dependence on imported components (notably China) – exposing supply chain risk
- Valuation concerns:
- Some analysts warn of rich pricing and limited margin of safety at current P/E valuations (~36×–77×)
- Others, including Anand Rathi, remain bullish on long‑term potential, citing leadership in security tech and strong growth prospects
0 Comments